The Center
Multiple Sclerosis Center Dresden
Patient Information
Contact MSC
Physicians & Nurses
Study Team
Neuropsychology
Mobility Center
The Mobility Center
Walking Assessment
Jump Assessment
DIERS
EMIQ
Projects
Neuroimmunological Laboratory
The NIL
Neurofilament light chain
Autonomic & Neuroendocrinological Functional Laboratory
The ANF
ANF Assessment
MS Living Lab
Management & Science
Team Management & Science
Projects
eHealth & Analytics
MSDS 3D
MSDS Clinic & Practice
MS-HRS
MTRS
Multiple Sclerosis Management
Aktuelles
Neuigkeiten
Publikationen
Veranstaltungen
Adventssymposium
MS Tag 2025
Multiple Sklerose 360°
Welt-MS-Tag 2021
Doktorarbeiten
Jobs
Kontakt
Spenden
Podcasts & Newsletter
Newsletter
Patienten-Podcast
Ärzte-Podcast
Neurovision
Digital calender 2026
Sherlock-MS-Blog
Studien
Interventionelle Studien
B-SHUTTLE
Nicht-interventionelle Studien
MS PATHS
Konectom
Sprachanalyse
English
Deutsch
English
Effects of obstructive sleep apnea treatment on neurodegenerative biomarker neurofilament light chain and cognitive performance
NIL
Jahr
Publikationsjahr
2024
Autoren
Autorenliste der Publikation
Sehr T, Akgün K, Benkert P, Kuhle J, Ziemssen T, Brandt MD.
Verlag
Publisher-Information
J Sleep Res. 2024 Feb 13:e14164.
Link
Zur Publikation (externer Server)
https://doi.org/10.1111/jsr.14164
Tags
Forschungsthemen
Neuroimmunologie
Andere
Andere
NIL
2024
Peripheral redox biomarkers in multiple sclerosis: associations with phenotype, cognition, and fatigue
Multiple Sclerosis
Jahr
2026
Neurofilament-Leichtkette (sNfL) als Instrument zur Beurteilung der Krankheitsaktivität und des Therapieansprechens bei Multipler Sklerose (MS)
NIL
Jahr
2026
From measurement to biomarker trajectories: platform-agnostic Z score analysis of serum NfL and GFAP in ocrelizumab-treated multiple sclerosis
NIL
Jahr
2026
Brain age gap in multiple sclerosis: associated with disability but independent of serum biomarkers
Multiple Sclerosis
Jahr
2026
Beyond B Cell Depletion: Adhesion and Activation Network Remodeling During Repeated Intravenous Anti-CD20 Therapy in Multiple Sclerosis
MS Treatments
Jahr
2026
